Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Eva Gupta, Joseph Accurso, Jason Sluzevich, David M. Menke, Han W Tun

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton’s tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.

Original languageEnglish (US)
Article number6067
Pages (from-to)164-166
Number of pages3
JournalRare Tumors
Volume7
Issue number4
DOIs
StatePublished - Dec 29 2015

Fingerprint

Immunomodulation
Lymphoma, Large B-Cell, Diffuse
Leg
Skin
Recurrence
Lymphoma
Agammaglobulinaemia tyrosine kinase
B-Lymphocytes
Radiotherapy
PCI 32765
Therapeutics

Keywords

  • Cutaneous diffuse large B-cell lymphoma
  • Ibrutinib
  • Lenalidomide

ASJC Scopus subject areas

  • Oncology
  • Histology

Cite this

Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. / Gupta, Eva; Accurso, Joseph; Sluzevich, Jason; Menke, David M.; Tun, Han W.

In: Rare Tumors, Vol. 7, No. 4, 6067, 29.12.2015, p. 164-166.

Research output: Contribution to journalArticle

@article{035bfdb90f734422bfcdfa330778e4b3,
title = "Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type",
abstract = "Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton’s tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.",
keywords = "Cutaneous diffuse large B-cell lymphoma, Ibrutinib, Lenalidomide",
author = "Eva Gupta and Joseph Accurso and Jason Sluzevich and Menke, {David M.} and Tun, {Han W}",
year = "2015",
month = "12",
day = "29",
doi = "10.4081/rt.2015.6067",
language = "English (US)",
volume = "7",
pages = "164--166",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",
number = "4",

}

TY - JOUR

T1 - Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type

AU - Gupta, Eva

AU - Accurso, Joseph

AU - Sluzevich, Jason

AU - Menke, David M.

AU - Tun, Han W

PY - 2015/12/29

Y1 - 2015/12/29

N2 - Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton’s tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.

AB - Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton’s tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.

KW - Cutaneous diffuse large B-cell lymphoma

KW - Ibrutinib

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=84952764357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952764357&partnerID=8YFLogxK

U2 - 10.4081/rt.2015.6067

DO - 10.4081/rt.2015.6067

M3 - Article

AN - SCOPUS:84952764357

VL - 7

SP - 164

EP - 166

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

IS - 4

M1 - 6067

ER -